Phase 1 Obesity Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are generally healthy, with no significant findings on physical examination, blood tests, urine tests, or heart tracing (ECG) at the time of screening
- People who show no signs of memory problems or dementia, as assessed by the trial doctor
- People who are not under any form of legal guardianship or court supervision
- People with a Body Mass Index (BMI) of 27.0 or higher at the time of screening (this means having a higher body weight relative to height)
- People whose body weight has been stable — meaning less than 5% change up or down — in the two months before screening, and between screening and the start of the trial
- People who agree to follow the contraception (birth control) requirements set out by the trial
Who may not be able to join:
- People who are pregnant, breastfeeding, or planning to become pregnant during the study
- People whose medical interview or physical examination reveals any condition that the trial doctor believes would make participation unsafe or would affect the person's ability to complete the study
- People with a history or current presence of any significant heart, lung, liver, kidney, digestive, hormonal, blood, neurological, psychiatric, or metabolic conditions, serious allergies, reduced fertility, cancer, or liver scarring (cirrhosis)
- People with any medical history or condition that could significantly affect how the body absorbs, processes, or removes medications
- People with a history of seizures or epilepsy (not including simple fever-related convulsions in childhood), or a history of significant head injury or infections of the brain or nervous system (such as meningitis)
- People with a history of acute or long-term metabolic acidosis (a condition where there is too much acid in the body), including diabetic ketoacidosis
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Trials, Hoffmann-La Roche
Phone: 888-662-6728 (U.S. Only)
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence and Severity of Adverse Events; Incidence of Abnormal Clinical Laboratory Test Results; Incidence of Abnormal Vital Sign Assessments; Incidence of Abnormal Electrocardiogram Parameters; Maximum Plasma Concentration Observed (Cmax) of Rosuvastatin, Administered Alone and in Combination with RO7795081; Time to Maximum Plasma Concentration (Tmax) of Rosuvastatin, Administered Alone and in Combination with RO7795081; Area Under the Plasma Concentration-Time Curve (AUC) from Time 0 to the Last Measurable Concentration (AUClast) of Rosuvastatin, Administered Alone and in Combination with R...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.